Expanding research in this area is critical for optimizing ferroptosis modulation and may pave the way for innovative therapeutic strategies that utilize NFE2L2 inhibition to overcome drug resistance and improve clinical outcomes across various cancer types. The gene discussed is NFE2L2; the disease is cancer.